Biological Activity of Weekly ONC201 in Adult Recurrent Glioblastoma Patients

Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

This paper reports the results of an investigation of the drug ONC201 in adults with recurrent glioblastoma (GBM). It found that ONC201 penetrated the blood-brain barrier and achieved intratumoral levels without toxicity. While most GBMs were not responsive, one patient with the mutation H3 K27M experienced a prolonged remission.

Go to full paper published in Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.